Women's Health Policy

CONTRACEPTIve care IN THE U.S.

New and noteworthy

Kennedy v. Braidwood and Preventive Services

On June 27, 2025, the U.S. Supreme Court ruled that the ACA requirement that most private insurers and Medicaid expansion programs cover preventive services recommended by the United States Preventive Services Task Force (USPSTF) with no cost-sharing is constitutional.

5 Key Facts About Medicaid and Pregnancy

As a primary payer for maternity care in the U.S., Medicaid is an integral component of maternal and infant health in the country. This brief examines Medicaid’s pregnancy and postpartum coverage and its support for strengthening and improving maternal health outcomes.

Medicaid Work Requirements and Women’s Coverage

This data note documents differences by sex in the work status of adult Medicaid enrollees ages 19-64 who were not receiving Supplemental Security Income (SSI) and were not dually eligible for Medicare in 2023, and highlights differences by parental status.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

21 - 30 of 862 Results

  • The Comstock Act: Implications for Abortion Care Nationwide 

    Issue Brief

    This brief provides background on the Comstock Act, reviews how it has been interpreted by the Biden Administration’s DOJ, and considers how it could be enforced by an administration that is hostile toward abortion to severely restrict the distribution of drugs and supplies used for abortion, with implications for abortion access in all states across the country.

  • Will Insurance Cover Over-the-Counter Contraceptive Pills? A Discussion of Coverage Options and Challenges

    Event Date:
    Event

    The U.S. Food and Drug Administration recently approved Opill—the first over-the-counter daily oral contraceptive pill in the United States. Beginning in early 2024, people will be able to purchase Opill without a prescription, expanding options for contraceptive access across the country. On September 15, 2023, a panel of experts joined Laurie Sobel, associate director for KFF’s Women’s Health Policy program, to explore approaches to covering over-the-counter oral contraception without a prescription. The panel discussed lessons learned from the implementation of private insurance or Medicaid coverage from the perspectives of various stakeholders.

  • Insurance Coverage of OTC Oral Contraceptives: Lessons from the Field

    Report

    This report is based on 35 structured interviews conducted from January to August 2023, with nearly 80 experts and key players such as pharmacists, health plans, and state Medicaid officials involved in the coverage and provision of OTC contraception in seven states with one or more of these coverage approaches (IL, NJ, NM, NY, OR, UT, and WA). It discusses the challenges and successes in coverage under private health insurance and Medicaid and reviews policy options for operationalizing insurance coverage of non-prescribed OTC contraception such as Opill.

  • Over-the-Counter Oral Contraceptive Pills

    Issue Brief

    Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

  • KFF Health Misinformation Tracking Poll Pilot

    Poll Finding

    The poll reveals that at least four in ten U.S. adults saying they’ve heard each of 10 specific false claims about COVID-19, reproductive health, and gun violence. While relatively small shares definitely believes the false claims, many more are uncertain about them. The survey also examines the public’s social and traditional media use and trust in sources of health information.

  • A National Survey of OBGYNs’ Experiences After Dobbs

    Report

    This report, based on a nationally representative survey of office-based OBGYNs practicing in the United States, examines the provision of sexual and reproductive health care provided by OBGYNs before and after the Dobbs decision, comparing the experiences of OBGYNs practicing in states where abortion is fully banned, states with gestational restrictions, and states where abortion remains available under most circumstances.